All News

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce the award of two new modelling and simulation contracts with the total value of £29,750.   Contract Award 1: Physiomics has secured a contract with a UK-based biotech firm specialising in AI-powered drug development. Building on an earlier projects announced...

Read More

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biometrics company supporting the development of new therapeutics and personalised medicine solutions, announces that Peter Sargent will be stepping down from his role as Executive Director and CEO of the Company to pursue other opportunities, with effect from 29 May 2026.   The Company has commenced its search to appoint a new CEO and further announcements...

Read More

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biometrics company supporting the development of new therapeutics and personalised medicine solutions, recently attended the American Conference on Pharmacometrics (ACoP) 2025 (18-21 October) – one of the key gatherings for those shaping the future of quantitative drug development – for the first time in a number of years.     Dr Mark Davies, Head of Quantitative Pharmacology...

Read More

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biometrics company supporting the development of new therapeutics and personalised medicine solutions, was pleased to attend BIO-Europe – Europe’s largest life sciences partnering event -  in Vienna this November 2025.     This year with over 5,800 attendees from the life sciences industry, Physiomics’ Head of Business Development, Hayley Close and Head of Biometrics, Jesse Thissen, attended...

Read More

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biometrics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce that all resolutions put to shareholders at the Company’s annual general meeting, held earlier today, were duly passed. Voting was conducted by a show of hands and inclusive of votes received by the Company by way of proxy.   Click...

Read More

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biometrics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to provide notice of the Company’s Annual General Meeting (“AGM”).   The AGM will be held at 10.30 a.m. on 18 November 2025 at Bee House, 140 Eastern Avenue, Milton Park, Oxfordshire, OX14 4SB.   Shareholders will shortly be sent either printed copies of...

Read More

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, announces that, effective from 1 October 2025, its registered office will change to Milton Park Innovation Centre, 99 Park Drive, Milton Park, Oxfordshire, OX14 4RY. For more information about Physiomics and its services, please visit www.physiomics.co.uk.     Enquiries:   Physiomics plc Dr Peter Sargent, CEO +44 (0)1235 841575   Hybridan...

Read More

Physiomics plc (AIM: PYC), a leading mathematical modelling and data science company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce that the Company will be releasing its audited results for the year ended 30 June 2025, on 29 September 2025.   The Company further announces that following the merger of its previous auditor, Shipleys LLP, with Moore Kingston Smith LLP (“MKS”)...

Read More

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce the award of a second contract by a UK-based biotech client at the forefront of AI-driven drug development. This follows the successful completion of a previous project with the same client, which was announced in June 2024 and...

Read More